ijms-logo

Journal Browser

Journal Browser

Non-Coding RNA: Biomarkers for Cardiovascular Diseases

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 28 February 2025 | Viewed by 644

Special Issue Editor


E-Mail Website
Guest Editor
Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Av. Barcelona, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
Interests: biomarkers of cardiac remodeling

Special Issue Information

Dear Colleagues,

Non-coding RNAs (ncRNAs) are highly abundant RNA molecules that, although not translated into protein, play an important role in cellular processes. ncRNAs have the function of regulating gene expression at the transcriptional or post-transcriptional level. ncRNAs play essential roles in homeostasis, development, cell proliferation, differentiation, and apoptosis, as well as a wide variety of pathologies. There are several types of ncRNAs, and most of them are closely linked to epigenetic processes. ncRNAs are divided into two large groups: short non-coding RNAs with a length of less than 200nt, and long non-coding RNAs with a length of more than 200nt. Among these different types of short non-coding RNAs are microRNAs, Piwi-interacting RNAs, small interfering RNAs, small nuclear RNAs, small nucleolar RNAs, and circular RNAs. ncRNAs have been identified as being novel regulators of cardiovascular risk factors and may be important biomarker candidates for improving diagnostic and prognostic assessments in cardiovascular diseases. Furthermore, ncRNAs are emerging as novel therapeutic agents, thus providing new therapeutic targets, some of which are being used in clinical practice. In this Special Issue, we focus on the recent advances and approaches for the mechanisms of action and diagnostic or therapeutic uses of ncRNAs in cardiovascular diseases, such as atrial fibrillation, atherosclerosis, myocardial infarction, heart failure, or cardiotoxicity.

Dr. Isabel Moscoso
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiovascular diseases
  • non-coding RNA (ncRNA)
  • therapeutics
  • biomarkers
  • microRNA
  • lncRNA
  • siRNA

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

22 pages, 1982 KiB  
Review
Transforming Cardiotoxicity Detection in Cancer Therapies: The Promise of MicroRNAs as Precision Biomarkers
by Isabel Moscoso, Moisés Rodríguez-Mañero, María Cebro-Márquez, Marta E. Vilar-Sánchez, Valentina Serrano-Cruz, Iria Vidal-Abeijón, María Amparo Martínez-Monzonís, Pilar Mazón-Ramos, Milagros Pedreira, José Ramón González-Juanatey and Ricardo Lage
Int. J. Mol. Sci. 2024, 25(22), 11910; https://doi.org/10.3390/ijms252211910 - 6 Nov 2024
Viewed by 465
Abstract
Cardiotoxicity (CDTX) is a critical side effect of many cancer therapies, leading to increased morbidity and mortality if not addressed. Early detection of CDTX is essential, and while echocardiographic measures like global longitudinal strain offer promise in identifying early myocardial dysfunction, the search [...] Read more.
Cardiotoxicity (CDTX) is a critical side effect of many cancer therapies, leading to increased morbidity and mortality if not addressed. Early detection of CDTX is essential, and while echocardiographic measures like global longitudinal strain offer promise in identifying early myocardial dysfunction, the search for reliable biomarkers continues. MicroRNAs (miRNAs) are emerging as important non-coding RNA molecules that regulate gene expression post-transcriptionally, influencing key biological processes such as the cell cycle, apoptosis, and stress responses. In cardiovascular diseases, miRNAs have demonstrated potential as biomarkers due to their stability in circulation and specific expression patterns that reflect pathological changes. Certain miRNAs have been linked to CDTX and hold promise for early detection, prognosis, and therapeutic targeting. These miRNAs not only assist in identifying early cardiac injury, but also offer opportunities for personalized interventions by modulating their expression to influence disease progression. As research advances, integrating miRNA profiling with traditional diagnostic methods could enhance the management of CDTX in cancer patients, paving the way for improved patient outcomes and more tailored therapeutic strategies. Further clinical studies are essential to validate the clinical utility of miRNAs in managing CDTX. Full article
(This article belongs to the Special Issue Non-Coding RNA: Biomarkers for Cardiovascular Diseases)
Show Figures

Figure 1

Back to TopTop